Author:
Venkatesan Kirthika,Cheryeth Mabel Mary James,Verghese Anna Tintu,Mathews Arpita Mariam,Ravisankar Nikitha,Unnikrishnan Parvathy,Prakash Vishakh,Harimohan Hridya,Haroon Nisha Nigil,James Sandra,Cherian Somy
Publisher
Springer Science and Business Media LLC
Reference31 articles.
1. R. Agarwal, G. Filippatos, B. Pitt, S.D. Anker, P. Rossing, A. Joseph, P. Kolkhof, C. Nowack, M. Gebel, L.M. Ruilope, G.L. Bakris; FIDELIO-DKD and FIGARO-DKD investigators, Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: he FIDELITY pooled analysis. Eur. Heart J. 43(6), 474–484 (2022). https://doi.org/10.1093/eurheartj/ehab777
2. Centers for Disease Control and Prevention (CDC). Diabetes and Chronic Kidney Disease. Retrieved from https://www.cdc.gov/diabetes/managing/diabetes-kidney-disease.html#:~:text=CKD%20is%20common%20in%20people,diabetes%20can%20cause%20kidney%20disease (2023)
3. H. Li, W. Lu, A. Wang, H. Jiang, J. Lyu, Changing epidemiology of chronic kidney disease as a result of type 2 diabetes mellitus from 1990 to 2017: Estimates from Global Burden of Disease 2017. J. Diab. Investig. 12(3), 346–356 (2021). https://doi.org/10.1111/jdi.13355
4. A. Makhlough, Z. Kashi, O. Akha, E. Zaboli, J. Yazdanicharati, Effect of spironolactone on diabetic nephropathy compared to the combination of spironolactone and losartan. Nephro-Urol. Monthly 6(1), e12148 (2014. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3968951/
5. D. Kawanami, Y. Takashi, Y. Muta, N. Oda, D. Nagata, H. Takahashi, M. Tanabe, Mineralocorticoid receptor antagonists in diabetic kidney disease. Front. Pharmacol. 12, 754239 (2021. https://www.frontiersin.org/articles/10.3389/fphar.2021.754239/full